Tags

Type your tag names separated by a space and hit enter

Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma.
Am J Respir Crit Care Med 1997; 156(6):1731-7AJ

Abstract

Short-acting beta(2)-agonists provide greater protection to bronchoconstriction induced by adenosine-5'-monophosphate (AMP) than does methacholine. Because AMP produces bronchoconstriction through release of mediators from mast cells, and methacholine directly constricts airway smooth muscle, this suggests that beta(2)-agonists stabilize mast cells in vivo. This in vivo property has not been demonstrated with long-acting beta(2)-agonists. We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma. In the first study, 19 patients attended on four occasions to inhale salmeterol 50 micrograms or placebo 2 h before challenge with AMP or histamine. In the second study 16 patients (13 of whom had participated in the first study) were studied in a similar fashion but inhaled albuterol 400 micrograms or placebo 30 min prior to challenge. Salmeterol reduced AR to AMP and histamine by 3.4 +/- 0.3 and 3.9 +/- 0.3 doubling doses, respectively (NS). In contrast, albuterol demonstrated a greater protective effect on AMP than on histamine, reducing AR by 5.1 +/- 0.3 and 3.8 +/- 0.2 doubling doses, respectively (p < 0.005). Thus, in contrast to albuterol, salmeterol did not demonstrate mast-cell stabilizing properties in vivo at a time corresponding to maximal bronchodilatation. These findings might be explained by the unique pharmacologic profile of salmeterol in combination with the differential beta(2)-adrenoceptor pharmacology of bronchial mast cells and bronchial smooth muscle.

Authors+Show Affiliations

Royal Brompton Clinical Studies Unit, Department of Thoracic Medicine, Imperial College School of Medicine, London, United Kingdom.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9412548

Citation

Taylor, D A., et al. "Comparison of Salmeterol and Albuterol-induced Bronchoprotection Against Adenosine Monophosphate and Histamine in Mild Asthma." American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 6, 1997, pp. 1731-7.
Taylor DA, Jensen MW, Aikman SL, et al. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am J Respir Crit Care Med. 1997;156(6):1731-7.
Taylor, D. A., Jensen, M. W., Aikman, S. L., Harris, J. G., Barnes, P. J., & O'Connor, B. J. (1997). Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. American Journal of Respiratory and Critical Care Medicine, 156(6), pp. 1731-7.
Taylor DA, et al. Comparison of Salmeterol and Albuterol-induced Bronchoprotection Against Adenosine Monophosphate and Histamine in Mild Asthma. Am J Respir Crit Care Med. 1997;156(6):1731-7. PubMed PMID: 9412548.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. AU - Taylor,D A, AU - Jensen,M W, AU - Aikman,S L, AU - Harris,J G, AU - Barnes,P J, AU - O'Connor,B J, PY - 1997/12/31/pubmed PY - 1997/12/31/medline PY - 1997/12/31/entrez SP - 1731 EP - 7 JF - American journal of respiratory and critical care medicine JO - Am. J. Respir. Crit. Care Med. VL - 156 IS - 6 N2 - Short-acting beta(2)-agonists provide greater protection to bronchoconstriction induced by adenosine-5'-monophosphate (AMP) than does methacholine. Because AMP produces bronchoconstriction through release of mediators from mast cells, and methacholine directly constricts airway smooth muscle, this suggests that beta(2)-agonists stabilize mast cells in vivo. This in vivo property has not been demonstrated with long-acting beta(2)-agonists. We undertook two double-blind, randomized, crossover, placebo-controlled studies to investigate the effects of salmeterol and albuterol on airway responsiveness (AR) to AMP and histamine in patients with mild asthma. In the first study, 19 patients attended on four occasions to inhale salmeterol 50 micrograms or placebo 2 h before challenge with AMP or histamine. In the second study 16 patients (13 of whom had participated in the first study) were studied in a similar fashion but inhaled albuterol 400 micrograms or placebo 30 min prior to challenge. Salmeterol reduced AR to AMP and histamine by 3.4 +/- 0.3 and 3.9 +/- 0.3 doubling doses, respectively (NS). In contrast, albuterol demonstrated a greater protective effect on AMP than on histamine, reducing AR by 5.1 +/- 0.3 and 3.8 +/- 0.2 doubling doses, respectively (p < 0.005). Thus, in contrast to albuterol, salmeterol did not demonstrate mast-cell stabilizing properties in vivo at a time corresponding to maximal bronchodilatation. These findings might be explained by the unique pharmacologic profile of salmeterol in combination with the differential beta(2)-adrenoceptor pharmacology of bronchial mast cells and bronchial smooth muscle. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/9412548/Comparison_of_salmeterol_and_albuterol_induced_bronchoprotection_against_adenosine_monophosphate_and_histamine_in_mild_asthma_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm.156.6.9703047?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -